Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol (883 views visite)
Eur J Clin Pharmacol Springer Verlag (ISSN: 0031-6970, 1432-1041), 1986; 29(6): 717-719.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 1.219, 5-year impact factor Impact factor a 5 anni: 2.258
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0022651542&partnerID=40&md5=3511ea7ddcf9866e5792683417b00aef
Keywords Parole chiave: Antihypertensive Activity, Cyclo-Oxygenase, Drug Interaction, Drug Metabolizing Enzymes, Oxprenolol, Prostaglandins, Sulphinpyrazone, Placebo, Sulfinpyrazone, Adverse Drug Reaction, Blood Pressure, Cardiovascular System, Clinical Article, Drug Therapy, Heart, Heart Rate, Human, Oral Drug Administration, Priority Journal, Adult, Cardiac Output, Clinical Trials, Double-Blind Method, Female, Middle Aged, Random Allocation,
Affiliations Affiliazioni:
Clinica Medica, Institute of Internal Medicine and Internal Diseases, 2nd Medical School, University of Naples, Naples, Italy
References Riferimenti:
Not available. Non disponibili.
Eur J Clin Pharmacol Springer Verlag (ISSN: 0031-6970, 1432-1041), 1986; 29(6): 717-719.
Export to Esporta in BibTeX Export to Esporta in EndNote
Paper type Tipo di articolo: Journal Article,
Impact factor: 1.219, 5-year impact factor Impact factor a 5 anni: 2.258
Url: http://www.scopus.com/inward/record.url?eid=2-s2.0-0022651542&partnerID=40&md5=3511ea7ddcf9866e5792683417b00aef
Keywords Parole chiave: Antihypertensive Activity, Cyclo-Oxygenase, Drug Interaction, Drug Metabolizing Enzymes, Oxprenolol, Prostaglandins, Sulphinpyrazone, Placebo, Sulfinpyrazone, Adverse Drug Reaction, Blood Pressure, Cardiovascular System, Clinical Article, Drug Therapy, Heart, Heart Rate, Human, Oral Drug Administration, Priority Journal, Adult, Cardiac Output, Clinical Trials, Double-Blind Method, Female, Middle Aged, Random Allocation,
Affiliations Affiliazioni:
Clinica Medica, Institute of Internal Medicine and Internal Diseases, 2nd Medical School, University of Naples, Naples, Italy
References Riferimenti:
Not available. Non disponibili.
Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol
The interfering effect of sulphinpyrazone, a uricosuric agent which reduces the activity of cyclo-oxygenase, with the antihypertensive activity of oxprenolol, a non-cardioselective beta-blocker with sympathomimetic activity, has been evaluated. Ten patients with primary arterial hypertension of mild to moderate degree entered a randomized doubleblind cross-over study versus placebo. They were given oxprenolol + placebo or oxprenolol + sulphinpyrazone for 15 days, and then the treatments were crossed-over for a further 15 days. Oxprenolol significantly reduced blood pressure (161±3/101±1 vs 149±4/96±2 mmHg) and heart rate (72±3 vs 66±3 beats/min). During administration of the combination with sulphinpyrazone the blood pressure increased to its pretreatment level (156±5/101±2 mmHg). The effect of oxprenolol on heart rate was not influenced by the combined treatment (67±6 beats/min). The results may be explained by 1) sulphinpyrazone-induced inhibition of prostaglandin synthesis, which could interfere with the antihypertensive activity of oxprenolol, or 2) sulphinpyrazone-induced acceleration of the metabolism of oxprenolol. © 1986 Springer-Verlag.
The interfering effect of sulphinpyrazone, a uricosuric agent which reduces the activity of cyclo-oxygenase, with the antihypertensive activity of oxprenolol, a non-cardioselective beta-blocker with sympathomimetic activity, has been evaluated. Ten patients with primary arterial hypertension of mild to moderate degree entered a randomized doubleblind cross-over study versus placebo. They were given oxprenolol + placebo or oxprenolol + sulphinpyrazone for 15 days, and then the treatments were crossed-over for a further 15 days. Oxprenolol significantly reduced blood pressure (161±3/101±1 vs 149±4/96±2 mmHg) and heart rate (72±3 vs 66±3 beats/min). During administration of the combination with sulphinpyrazone the blood pressure increased to its pretreatment level (156±5/101±2 mmHg). The effect of oxprenolol on heart rate was not influenced by the combined treatment (67±6 beats/min). The results may be explained by 1) sulphinpyrazone-induced inhibition of prostaglandin synthesis, which could interfere with the antihypertensive activity of oxprenolol, or 2) sulphinpyrazone-induced acceleration of the metabolism of oxprenolol. © 1986 Springer-Verlag.
Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol
No results. Nessun risultato. |
Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol
Korotkyi OH, Vovk AA, Dranitsina AS, Falalyeyeva TM, Dvorshchenko KO, Fagoonee S, Ostapchenko LI
* The influence of probiotic diet and chondroitin sulfate administration on Ptgs2, Tgfb1 and Col2a1 expression in rat knee cartilage during monoiodoacetate-induced osteoarthritis (230 visite)
Hepatology (ISSN: 0026-4806linking, 1827-1669electronic), 2019 Apr 1; 110(5): 419-424.
Impact Factor: 2.863
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Pappata S, Zampella E, Assante R
* Advances in SPECT Methodology (242 visite)
Int Rev Neurobiol (ISSN: 0074-77429780128154182, 2162-5514electronic), 2018 Sep; 141: 77-96.
Impact Factor: 3.36
Dettagli Esporta in BibTeX Esporta in EndNote
Musumeci D, Roviello GN, Montesarchio D
* An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies (478 visite)
Pharmacol Ther (ISSN: 0163-7258, 0163-7258linking), 2014 Mar; 141(3): 347-357.
Impact Factor: 9.723
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Bergamo P, Luini A, Ruvo M, Gogliettino M, Langella E, Saviano M, Hegde RN, Sandomenico A, Rossi M
* Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation (398 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2011 Oct 10; 6(10): e25888-e25888.
Impact Factor: 4.092
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, Truppo E, Pedone C, Supuran CT, De Simone G
* The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: The carbonic anhydrase I-topiramate complex (379 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2010 Sep 7; 8(15): 3528-3533.
Impact Factor: 3.451
Dettagli Esporta in BibTeX Esporta in EndNote
Nicoletti VG, Santoro AM, Grasso G, Vagliasindi LI, Giuffrida ML, Cuppari C, Purrello VS, Stella AMG, Rizzarelli E
* Carnosine interaction with nitric oxide and astroglial cell protection (587 visite)
Journal Of Neuroscience Research (ISSN: 0360-4012), 2007 Sep 1; 85(10): 2239-2245.
Impact Factor: 3.268
Dettagli Esporta in BibTeX Esporta in EndNote
Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G
* Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity (557 visite)
Neuroreport (ISSN: 0959-4965), 2005 Sep 1; 16(11): 1223-1226.
Impact Factor: 1.995
Dettagli Esporta in BibTeX Esporta in EndNote
Lauceri R, Purrello R, Shetty SJ, Vicente MGH
* Interactions of anionic carboranylated porphyrins with DNA [3] (293 visite)
J Am Chem Soc (ISSN: 0002-7863, 0002-2786, 1520-5126), 2001 Jun 20; 123(24): 5835-5836.
Impact Factor: 6.079
Dettagli Esporta in BibTeX Esporta in EndNote
Ferrara LA, Iannuzzi R, Gaeta I, Mancini M, Guida L, Marotta T
Left ventricular hypertrophy and hypertension (332 visite)
Clin Exp Hypertens Informa Healthcare, 1996 Jul; 15(6): 1025-1032.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Ferrara LA, Marotta T, Mancini Marcello, Fasano ML, Pasanisi F, Mancini M
Sulphinpyrazone-Induced Decrease In Antihypertensive Activity Of Beta-Blockers (160 visite)
Second European Meeting On Hypertension Milan, 1985 Dec; N/D: 171-171.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Marletta F, Rizzarelli E, Mangiameli A, Brogna A, Sammartano S, Monaco S, Blasi A
Effects of graded doses of copper complexes of L-aminoacids on gastric acid secretion in rats (1273 visite)
Boll Soc Ital Biol Sper (ISSN: 0037-8771), 1979 Apr 30; 55(8): 769-775.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
11 Records (10 escludendo Abstract e Conferenze).
Impact factor totale: 34.831 (34.831 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 34.619 (34.619 escludendo Abstract e Conferenze).
Vai a fine pagina Versione per copia e incolla facile Esporta tutto in BibTeX Esporta tutto in EndNote
Korotkyi OH, Vovk AA, Dranitsina AS, Falalyeyeva TM, Dvorshchenko KO, Fagoonee S, Ostapchenko LI
* The influence of probiotic diet and chondroitin sulfate administration on Ptgs2, Tgfb1 and Col2a1 expression in rat knee cartilage during monoiodoacetate-induced osteoarthritis (230 visite)
Hepatology (ISSN: 0026-4806linking, 1827-1669electronic), 2019 Apr 1; 110(5): 419-424.
Impact Factor: 2.863
Dettagli Esporta in BibTeX Esporta in EndNote
Cuocolo A, Pappata S, Zampella E, Assante R
* Advances in SPECT Methodology (242 visite)
Int Rev Neurobiol (ISSN: 0074-77429780128154182, 2162-5514electronic), 2018 Sep; 141: 77-96.
Impact Factor: 3.36
Dettagli Esporta in BibTeX Esporta in EndNote
Musumeci D, Roviello GN, Montesarchio D
* An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies (478 visite)
Pharmacol Ther (ISSN: 0163-7258, 0163-7258linking), 2014 Mar; 141(3): 347-357.
Impact Factor: 9.723
Dettagli Esporta in BibTeX Esporta in EndNote
Palmieri G, Bergamo P, Luini A, Ruvo M, Gogliettino M, Langella E, Saviano M, Hegde RN, Sandomenico A, Rossi M
* Acylpeptide hydrolase inhibition as targeted strategy to induce proteasomal down-regulation (398 visite)
Plosone (ISSN: 1932-6203, 1932-6203electronic), 2011 Oct 10; 6(10): e25888-e25888.
Impact Factor: 4.092
Dettagli Esporta in BibTeX Esporta in EndNote
Alterio V, Monti SM, Truppo E, Pedone C, Supuran CT, De Simone G
* The first example of a significant active site conformational rearrangement in a carbonic anhydrase-inhibitor adduct: The carbonic anhydrase I-topiramate complex (379 visite)
Org Biomol Chem (ISSN: 1477-0520, 1477-0539, 1477-0539electronic), 2010 Sep 7; 8(15): 3528-3533.
Impact Factor: 3.451
Dettagli Esporta in BibTeX Esporta in EndNote
Nicoletti VG, Santoro AM, Grasso G, Vagliasindi LI, Giuffrida ML, Cuppari C, Purrello VS, Stella AMG, Rizzarelli E
* Carnosine interaction with nitric oxide and astroglial cell protection (587 visite)
Journal Of Neuroscience Research (ISSN: 0360-4012), 2007 Sep 1; 85(10): 2239-2245.
Impact Factor: 3.268
Dettagli Esporta in BibTeX Esporta in EndNote
Marrazzo A, Caraci F, Salinaro ET, Su TP, Copani A, Ronsisvalle G
* Neuroprotective effects of sigma-1 receptor agonists against beta-amyloid-induced toxicity (557 visite)
Neuroreport (ISSN: 0959-4965), 2005 Sep 1; 16(11): 1223-1226.
Impact Factor: 1.995
Dettagli Esporta in BibTeX Esporta in EndNote
Lauceri R, Purrello R, Shetty SJ, Vicente MGH
* Interactions of anionic carboranylated porphyrins with DNA [3] (293 visite)
J Am Chem Soc (ISSN: 0002-7863, 0002-2786, 1520-5126), 2001 Jun 20; 123(24): 5835-5836.
Impact Factor: 6.079
Dettagli Esporta in BibTeX Esporta in EndNote
Ferrara LA, Iannuzzi R, Gaeta I, Mancini M, Guida L, Marotta T
Left ventricular hypertrophy and hypertension (332 visite)
Clin Exp Hypertens Informa Healthcare, 1996 Jul; 15(6): 1025-1032.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Ferrara LA, Marotta T, Mancini Marcello, Fasano ML, Pasanisi F, Mancini M
Sulphinpyrazone-Induced Decrease In Antihypertensive Activity Of Beta-Blockers (160 visite)
Second European Meeting On Hypertension Milan, 1985 Dec; N/D: 171-171.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
Marletta F, Rizzarelli E, Mangiameli A, Brogna A, Sammartano S, Monaco S, Blasi A
Effects of graded doses of copper complexes of L-aminoacids on gastric acid secretion in rats (1273 visite)
Boll Soc Ital Biol Sper (ISSN: 0037-8771), 1979 Apr 30; 55(8): 769-775.
Impact Factor: 0
Dettagli Esporta in BibTeX Esporta in EndNote
11 Records (10 escludendo Abstract e Conferenze).
Impact factor totale: 34.831 (34.831 escludendo Abstract e Conferenze).
Impact factor a 5 anni totale: 34.619 (34.619 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Massimiliano Sorbillo on in data Sunday 12 July 2020, 13:15:17
883 views visite. Last view on Ultima visita in data Saturday 16 October 2021, 12:30:10
ibb.cnr.it